Cardiomyocyte autophagy and cancer chemotherapy

Journal of Molecular and Cellular Cardiology

Volumn 71, Issue , 2014, Pages 54-61

  Li, Dan L ^a   Hill, Joseph A ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Autophagy; Cardiomyocyte; Cardiomyopathy; Chemotherapy

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CHLOROQUINE; DASATINIB; DOXORUBICIN; EPIRUBICIN; EVEROLIMUS; HYDROXYCHLOROQUINE; IMATINIB; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NILOTINIB; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRASTUZUMAB;

ADJUVANT THERAPY; AUTOPHAGY; BIOLOGICAL MONITORING; BREAST CANCER; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; CLINICAL EFFECTIVENESS; CONCENTRATION RESPONSE; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CELL; HEMATOLOGIC MALIGNANCY; HUMAN; IN VIVO STUDY; KIDNEY CARCINOMA; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MANTLE CELL LYMPHOMA; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; RESTRICTIVE CARDIOMYOPATHY; REVIEW; SARCOMA; SOLID TUMOR; TREATMENT DURATION; UPREGULATION; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; NEOPLASMS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; AUTOPHAGY; CARDIOMYOPATHIES; HUMANS; MYOCYTES, CARDIAC; NEOPLASMS;

EID: 84899936796     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2013.11.007     Document Type: Review

References (86)

1. Valdivieso M., Kujawa A.M., Jones T., Baker L.H. Cancer survivors in the United States: a review of the literature and a call to action. Int J Med Sci 2012, 9:163-173.
2. van der Pal H.J., van Dalen E.C., van Delden E., van Dijk I.W., Kok W.E., Geskus R.B., et al. High risk of symptomatic cardiac events in childhood cancer survivors. J Clin Oncol 2012, 30:1429-1437.
3. Khakoo A.Y., Yeh E.T. Therapy insight: Management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy. Nat Clin Pract Oncol 2008, 5:655-667.
4. Albini A., Pennesi G., Donatelli F., Cammarota R., De Flora S., Noonan D.M. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 2010, 102:14-25.
5. Sereno M., Brunello A., Chiappori A., Barriuso J., Casado E., Belda C., et al. Cardiac toxicity: old and new issues in anti-cancer drugs. Clin Transl Oncol 2008, 10:35-46.
6. Ky B., Vejpongsa P., Yeh E.T., Force T., Moslehi J.J. Emerging paradigms in cardiomyopathies associated with cancer therapies. Circ Res 2013, 113:754-764.
7. Lavandero S., Troncoso R., Rothermel B.A., Martinet W., Sadoshima J., Hill J.A. Cardiovascular autophagy: concepts, controversies and perspectives. Autophagy 2013, 9.
8. Mizushima N., Komatsu M. Autophagy: renovation of cells and tissues. Cell 2011, 147:728-741.
9. Levine B., Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008, 132:27-42.
10. Hara T., Nakamura K., Matsui M., Yamamoto A., Nakahara Y., Suzuki-Migishima R., et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 2006, 441:885-889.
11. Masiero E., Agatea L., Mammucari C., Blaauw B., Loro E., Komatsu M., et al. Autophagy is required to maintain muscle mass. Cell Metab 2009, 10:507-515.
12. Taneike M., Yamaguchi O., Nakai A., Hikoso S., Takeda T., Mizote I., et al. Inhibition of autophagy in the heart induces age-related cardiomyopathy. Autophagy 2010, 6:600-606.
13. Hamasaki M., Furuta N., Matsuda A., Nezu A., Yamamoto A., Fujita N., et al. Autophagosomes form at ER-mitochondria contact sites. Nature 2013, 495:389-393.
14. Yang Z., Klionsky D.J. Eaten alive: a history of macroautophagy. Nat Cell Biol 2010, 12:814-822.
15. Kim J., Kim Y.C., Fang C., Russell R.C., Kim J.H., Fan W., et al. Differential regulation of distinct Vps34 complexes by AMPK in nutrient stress and autophagy. Cell 2013, 152:290-303.
16. Maiuri M.C., Le Toumelin G., Criollo A., Rain J.C., Gautier F., Juin P., et al. Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1. EMBO J 2007, 26:2527-2539.
17. Pattingre S., Tassa A., Qu X., Garuti R., Liang X.H., Mizushima N., et al. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 2005, 122:927-939.
18. Tanaka Y., Guhde G., Suter A., Eskelinen E.L., Hartmann D., Lullmann-Rauch R., et al. Accumulation of autophagic vacuoles and cardiomyopathy in LAMP-2-deficient mice. Nature 2000, 406:902-906.
19. Nishino I., Fu J., Tanji K., Yamada T., Shimojo S., Koori T., et al. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature 2000, 406:906-910.
20. Sardiello M., Palmieri M., di Ronza A., Medina D.L., Valenza M., Gennarino V.A., et al. A gene network regulating lysosomal biogenesis and function. Science 2009, 325:473-477.
21. Settembre C., Di Malta C., Polito V.A., Garcia Arencibia M., Vetrini F., Erdin S., et al. TFEB links autophagy to lysosomal biogenesis. Science 2011, 332:1429-1433.
22. Liang C., Lee J.S., Inn K.S., Gack M.U., Li Q., Roberts E.A., et al. Beclin1-binding UVRAG targets the class C Vps complex to coordinate autophagosome maturation and endocytic trafficking. Nat Cell Biol 2008, 10:776-787.
23. Matsunaga K., Saitoh T., Tabata K., Omori H., Satoh T., Kurotori N., et al. Two beclin 1-binding proteins, Atg14L and rubicon, reciprocally regulate autophagy at different stages. Nat Cell Biol 2009, 11:385-396.
24. Jager S., Bucci C., Tanida I., Ueno T., Kominami E., Saftig P., et al. Role for Rab7 in maturation of late autophagic vacuoles. J Cell Sci 2004, 117:4837-4848.
25. Klionsky D.J., Abdalla F.C., Abeliovich H., Abraham R.T., Acevedo-Arozena A., Adeli K., et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012, 8:445-544.
26. Linares J.F., Duran A., Yajima T., Pasparakis M., Moscat J., Diaz-Meco M.T. K63 polyubiquitination and activation of mTOR by the p62-TRAF6 complex in nutrient-activated cells. Mol Cell 2013, 51:283-296.
27. Komatsu M., Kurokawa H., Waguri S., Taguchi K., Kobayashi A., Ichimura Y., et al. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat Cell Biol 2010, 12:213-223.
28. Jain A., Lamark T., Sjottem E., Larsen K.B., Awuh J.A., Overvatn A., et al. p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription. J Biol Chem 2010, 285:22576-22591.
29. Kimura S., Noda T., Yoshimori T. Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. Autophagy 2007, 3:452-460.
30. Kanamori H., Takemura G., Maruyama R., Goto K., Tsujimoto A., Ogino A., et al. Functional significance and morphological characterization of starvation-induced autophagy in the adult heart. Am J Pathol 2009, 174:1705-1714.
31. Shimomura H., Terasaki F., Hayashi T., Kitaura Y., Isomura T., Suma H. Autophagic degeneration as a possible mechanism of myocardial cell death in dilated cardiomyopathy. Jpn Circ J 2001, 65:965-968.
32. Sheppard R.J., Berger J., Sebag I.A. Cardiotoxicity of cancer therapeutics: current issues in screening, prevention, and therapy. Front Pharmacol 2013, 4:19.
33. Takemura G., Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 2007, 49:330-352.
34. Zhang S., Liu X., Bawa-Khalfe T., Lu L.S., Lyu Y.L., Liu L.F., et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 2012, 18:1639-1642.
35. Kobayashi S., Volden P., Timm D., Mao K., Xu X., Liang Q. Transcription factor GATA4 inhibits doxorubicin-induced autophagy and cardiomyocyte death. J Biol Chem 2010, 285:793-804.
36. Dimitrakis P., Romay-Ogando M.I., Timolati F., Suter T.M., Zuppinger C. Effects of doxorubicin cancer therapy on autophagy and the ubiquitin-proteasome system in long-term cultured adult rat cardiomyocytes. Cell Tissue Res 2012, 350:361-372.
37. Sishi B.J., Loos B., van Rooyen J., Engelbrecht A.M. Autophagy upregulation promotes survival and attenuates doxorubicin-induced cardiotoxicity. Biochem Pharmacol 2013, 85:124-134.
38. Kroemer G., Levine B. Autophagic cell death: the story of a misnomer. Nat Rev Mol Cell Biol 2008, 9:1004-1010.
39. He C., Levine B. The beclin 1 interactome. Curr Opin Cell Biol 2010, 22:140-149.
40. Force T., Kolaja K.L. Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat Rev Drug Discov 2011, 10:111-126.
41. Konorev E.A., Vanamala S., Kalyanaraman B. Differences in doxorubicin-induced apoptotic signaling in adult and immature cardiomyocytes. Free Radic Biol Med 2008, 45:1723-1728.
42. Lu L., Wu W., Yan J., Li X., Yu H., Yu X. Adriamycin-induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure. Int J Cardiol 2009, 134:82-90.
43. Ma Y., Zhang X., Bao H., Mi S., Cai W., Yan H., et al. Toll-like receptor (TLR) 2 and TLR4 differentially regulate doxorubicin induced cardiomyopathy in mice. PLoS One 2012, 7:e40763.
44. Zhang Y., Kang Y.M., Tian C., Zeng Y., Jia L.X., Ma X., et al. Overexpression of Nrdp1 in the heart exacerbates doxorubicin-induced cardiac dysfunction in mice. PLoS One 2011, 6:e21104.
45. Kawaguchi T., Takemura G., Kanamori H., Takeyama T., Watanabe T., Morishita K., et al. Prior starvation mitigates acute doxorubicin cardiotoxicity through restoration of autophagy in affected cardiomyocytes. Cardiovasc Res 2012, 96:456-465.
46. Singal P.K., Segstro R.J., Singh R.P., Kutryk M.J. Changes in lysosomal morphology and enzyme activities during the development of adriamycin-induced cardiomyopathy. Can J Cardiol 1985, 1:139-147.
47. Ding Y., Sun X., Huang W., Hoage T., Redfield M., Kushwaha S., et al. Haploinsufficiency of target of rapamycin attenuates cardiomyopathies in adult zebrafish. Circ Res 2011, 109:658-669.
48. Zhu H., Tannous P., Johnstone J.L., Kong Y., Shelton J.M., Richardson J.A., et al. Cardiac autophagy is a maladaptive response to hemodynamic stress. J Clin Invest 2007, 117:1782-1793.
49. Chen M.H., Kerkela R., Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 2008, 118:84-95.
50. Force T., Krause D.S., Van Etten R.A. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007, 7:332-344.
51. Kerkela R., Grazette L., Yacobi R., Iliescu C., Patten R., Beahm C., et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006, 12:908-916.
52. Ertmer A., Huber V., Gilch S., Yoshimori T., Erfle V., Duyster J., et al. The anticancer drug imatinib induces cellular autophagy. Leukemia 2007, 21:936-942.
53. Bellodi C., Lidonnici M.R., Hamilton A., Helgason G.V., Soliera A.R., Ronchetti M., et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 2009, 119:1109-1123.
54. Hu W., Lu S., McAlpine I., Jamieson J.D., Lee D.U., Marroquin L.D., et al. Mechanistic investigation of imatinib-induced cardiac toxicity and the involvement of c-Abl kinase. Toxicol Sci 2012, 129:188-199.
55. Herman E.H., Knapton A., Rosen E., Thompson K., Rosenzweig B., Estis J., et al. A multifaceted evaluation of imatinib-induced cardiotoxicity in the rat. Toxicol Pathol 2011, 39:1091-1106.
56. Schmidinger M., Zielinski C.C., Vogl U.M., Bojic A., Bojic M., Schukro C., et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008, 26:5204-5212.
57. Chu T.F., Rupnick M.A., Kerkela R., Dallabrida S.M., Zurakowski D., Nguyen L., et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007, 370:2011-2019.
58. Zhao Y., Xue T., Yang X., Zhu H., Ding X., Lou L., et al. Autophagy plays an important role in sunitinib-mediated cell death in H9c2 cardiac muscle cells. Toxicol Appl Pharmacol 2010, 248:20-27.
59. Kerkela R., Woulfe K.C., Durand J.B., Vagnozzi R., Kramer D., Chu T.F., et al. Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin Transl Sci 2009, 2:15-25.
60. Shimizu S., Takehara T., Hikita H., Kodama T., Tsunematsu H., Miyagi T., et al. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. Int J Cancer 2012, 131:548-557.
61. Lin J.C., Liu C.L., Lee J.J., Liu T.P., Ko W.C., Huang Y.C., et al. Sorafenib induces autophagy and suppresses activation of human macrophage. Int Immunopharmacol 2013, 15:333-339.
62. Shi Y.H., Ding Z.B., Zhou J., Hui B., Shi G.M., Ke A.W., et al. Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis. Autophagy 2011, 7:1159-1172.
63. Popat S., Smith I.E. Therapy insight: anthracyclines and trastuzumab-the optimal management of cardiotoxic side effects. Nat Clin Pract Oncol 2008, 5:324-335.
64. Crone S.A., Zhao Y.Y., Fan L., Gu Y., Minamisawa S., Liu Y., et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002, 8:459-465.
65. Azim H., Azim H.A., Escudier B. Trastuzumab versus lapatinib: the cardiac side of the story. Cancer Treat Rev 2009, 35:633-638.
66. Spector N.L., Yarden Y., Smith B., Lyass L., Trusk P., Pry K., et al. Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells. Proc Natl Acad Sci U S A 2007, 104:10607-10612.
67. Zhu X., Wu L., Qiao H., Han T., Chen S., Liu X., et al. Autophagy stimulates apoptosis in HER2-overexpressing breast cancers treated by lapatinib. J Cell Biochem 2013, 114:2643-2653.
68. Huang H.L., Chen Y.C., Huang Y.C., Yang K.C., Pan H., Shih S.P., et al. Lapatinib induces autophagy, apoptosis and megakaryocytic differentiation in chronic myelogenous leukemia K562 cells. PLoS One 2011, 6:e29014.
69. Han J., Hou W., Lu C., Goldstein L.A., Stolz D.B., Watkins S.C., et al. Interaction between Her2 and beclin-1 proteins underlies a new mechanism of reciprocal regulation. J Biol Chem 2013, 288:20315-20325.
70. Qu X., Yu J., Bhagat G., Furuya N., Hibshoosh H., Troxel A., et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest 2003, 112:1809-1820.
71. Takamura A., Komatsu M., Hara T., Sakamoto A., Kishi C., Waguri S., et al. Autophagy-deficient mice develop multiple liver tumors. Genes Dev 2011, 25:795-800.
72. Mathew R., Karp C.M., Beaudoin B., Vuong N., Chen G., Chen H.Y., et al. Autophagy suppresses tumorigenesis through elimination of p62. Cell 2009, 137:1062-1075.
73. Janku F., McConkey D.J., Hong D.S., Kurzrock R. Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol 2011, 8:528-539.
74. Mathew R., Karantza-Wadsworth V., White E. Role of autophagy in cancer. Nat Rev Cancer 2007, 7:961-967.
75. Wander S.A., Hennessy B.T., Slingerland J.M. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest 2011, 121:1231-1241.
76. Sabatini D.M. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006, 6:729-734.
77. Choi J.C., Muchir A., Wu W., Iwata S., Homma S., Morrow J.P., et al. Temsirolimus activates autophagy and ameliorates cardiomyopathy caused by lamin A/C gene mutation. Sci Transl Med 2012, 4:144ra02.
78. Buss S.J., Muenz S., Riffel J.H., Malekar P., Hagenmueller M., Weiss C.S., et al. Beneficial effects of mammalian target of rapamycin inhibition on left ventricular remodeling after myocardial infarction. J Am Coll Cardiol 2009, 54:2435-2446.
79. Carew J.S., Nawrocki S.T., Kahue C.N., Zhang H., Yang C., Chung L., et al. Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood 2007, 110:313-322.
80. Maclean K.H., Dorsey F.C., Cleveland J.L., Kastan M.B. Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. J Clin Invest 2008, 118:79-88.
81. Sotelo J., Briceno E., Lopez-Gonzalez M.A. Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2006, 144:337-343.
82. Teixeira R.A., Martinelli Filho M., Benvenuti L.A., Costa R., Pedrosa A.A., Nishioka S.A. Cardiac damage from chronic use of chloroquine: a case report and review of the literature. Arq Bras Cardiol 2002, 79:85-88.
83. Soong T.R., Barouch L.A., Champion H.C., Wigley F.M., Halushka M.K. New clinical and ultrastructural findings in hydroxychloroquine-induced cardiomyopathy-a report of 2 cases. Hum Pathol 2007, 38:1858-1863.
84. Tannous P., Zhu H., Nemchenko A., Berry J.M., Johnstone J.L., Shelton J.M., et al. Intracellular protein aggregation is a proximal trigger of cardiomyocyte autophagy. Circulation 2008, 117:3070-3078.
85. Nowis D., Maczewski M., Mackiewicz U., Kujawa M., Ratajska A., Wieckowski M.R., et al. Cardiotoxicity of the anticancer therapeutic agent bortezomib. Am J Pathol 2010, 176:2658-2668.
86. Bockorny M., Chakravarty S., Schulman P., Bockorny B., Bona R. Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature. Acta Haematol 2012, 128:244-247.